Naturcyte » Curqd Evidence

Scientific evidence of CurQD® in IBD

CurQD® was developed using a gut-directed strategy, helping the body re-establish balance — followed by structured long-term protocols intended to support ongoing stability over time.

This two-phase framework reflects the real-world needs of individuals managing long-term gut health: addressing short-term discomfort while aiming for lasting balance within the digestive system.

The studies below build on this scientific foundation, examining CurQD® through clinical research and real-world observation to better characterize its safety, tolerability, and biological effects.

Curcumin-Qingdai combination for patients with active Ulcerative Colitis: a randomized double-blinded placebo-controlled clinical trial. S.Ben Horin, N.Salomon, G.Karampekos, et al. Clin Gastroenterol Hepatol 2023

Randomized, double-blinded, placebo-controlled clinical trial to evaluate the clinical efficacy and safety of the combination of curcumin and QingDai (CurQD®) for patients with active ulcerative colitis.

This multicenter inical cinical trial used a combination of curcumin with Qing Dai (CurQD®) for 8 weeks in patients with active UC who had failed at least one line of treatment with drugs. This study included an 8-week maintenance reatment extension in those patients who had initially responded.

97.5% of patients had not previously responded to 5-ASA treatment.

48.8% of patients had not previously responded to biological or immunosuppressive treatment.

Nearly 1/3 of patients had not previously responded to immunosuppressive treatment.

At week 8, 50% of patients achieved clinical remission and 85.7% achieved clinical response.

Among patients who responded to CurQD®, after an additional 8 weeks of maintenance treatment with curcumin alone, it was observed that:

93% maintained clinical remission.

80% showed a significant reduction in calprotectin levels.

The authors concluded that CurQD® was superior to placebo in inducing response and clinical remission in patients with active UC, even in patients with moderate to severe activity, of whom half had received biologics or immunosuppressors..

An induction phase with CurQD®, followed by maintenance with curcumin (Qura) maximizes the efficacy and safety of this combined treatment.

Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study

Retrospective multicentre cohort study to evaluate the efficacy of the curcumin and QingDai combination (CurQD®) in patients with active ulcerative colitis: real-world clinical practice experience.

Retrospective multicentre study including 88 patients with UC from 5 medical centres with active disease at the start of treatment.

82.9% had not previously responded to steroids.

43.2% had not previously responded to at least one biologic drug or a small molecule.

28.4% had not previously responded tor ore than 2 biologic drugs or a small molecule.

At 12 weeks:

70.4% of patients showed clinical response.

51.1% of patients achieved clinical remission.

Of the patients who had received treatment with biologic drug or small molecule, between weeks 8-12, 72.3% showed clinical response and 44.7% achieved clinical remission.

Of patients receiving steroid treatment at the start, 26.9% achieved steroid-free clinical remission between weeks 8-12.

Of patients on steroid treatment at the start, 50% had discontinued steroids at the end of induction.

The study shows that the combination of curcumin and Qing Dai (CurQD®) is effective in inducing response and remission in patients with active UC, even in those with no previous response to biologics or small molecules.

Curcumin-QingDai Combination as Treatment for Moderate-Severe Ulcerative Colitis. Case Rep. Gastroenterol. 2022

Curcumin and QingDai combination (CurQD®) in patients with moderate to severe ulcerative colitis: Presentation of two cases.

Clinical cases of two UC patients: These were two of the first patients treated with the combination of Qing Dai and curcumin, and both, five years later, remain in remission without additional pharmacological treatment.

Patient 1 was 24 years old and had suffered from extensive severe UC for 2 years, requiring prolonged hospitalization. Although he showed improvement with infliximab, severe symptoms persisted, including bleeding. Within 10 days of starting CurQD® treatment, the bleeding stopped and, after several weeks, the patient achieved complete remission. Since then, 31 months later, he has maintained complete clinical remission without reporting adverse effects.

Patient 2 was 56 years old and had extensive UC. She did not respond to mesalamine and symptoms did not improve with budesonide-MMX (including bleeding, weakness, and abdominal pain). After starting CurQD® treatment , patient’s symptoms improved rapidly. At 5 months, she showed complete mucosal healing

Treatment with CurQD® achieved complete remission, mucosal healing, and long-term remission maintenance.

These clinical experiences show that CurQD® is effective in patients with moderate to severe UC, even in patients who have not previously responded to biologics and/or steroids.

Scientific evidence of CurQD® in IBD

CONTACT US

TO REQUEST ADDITIONAL INFORMATION

© 2023 Naturcyte. all rights reserved.

legal notice

PRIVACY POLICY

cookie policy

Terms of service and refund policy

Social media privacy policy

Política de devolución